INTRODUCTION
Germinal centres (GCs) are secondary lymphoid organs in which somatic hypermutation, affinity maturation and class switch recombination occur, thus producing high-affinity antibodies in humoral immunity. 1 During the multistep process of GC reactions, follicular helper T (Tfh) cells interact closely with B cells to support B-cell survival, differentiation and proliferation via direct contact and soluble signal. 2 It was not until 10 years ago that Tfh cells were broadly acknowledged among immunologists with B-cell leukaemia/lymphoma 6 (Bcl-6) discovered as a lineage-defining transcription factor (TF) of Tfh cells. 2 Although various mechanisms have been defined, the understanding of GC reactions is still elusive.
A subset of regulatory T (Treg) cells expressing C-X-C chemokine receptor type 5 (CXCR5) was first established in human tonsils. 3, 4 Then, in 2011, three separate articles described their physiology in mice. [5] [6] [7] 8 Nonetheless, Tfr cells together with Tfh cells harbour less diverse repertoires relative to Treg cells. 9 Recent studies have investigated this population in a wide range of diseases and have gained some progress.
This review discusses the physiology, pathology, discrepancies and challenges of Tfr cells, especially their alterations and potential roles in human diseases.
DISTRIBUTION, DIFFERENTIATION AND DEVELOPMENT OF TFR CELLS
Follicular regulatory T cells have been found in the spleen, lymph nodes (LNs), lymph or other lymphoid tissues such as Peyer's patches, and also in blood. Few Tfr cells are located within the GC, whereas most of them with low levels of PD-1 are located surrounding the GC. 10 Unlike Tfh cells, which are derived from na€ ıve CD4 + T cells, 11 Tfr cells are mainly derived from thymic Treg cells. [5] [6] [7] In addition, Tfr cells are also derived from Foxp3 À precursors in a PD-L1-dependent manner using certain adjuvants. 12 The full differentiation of Tfr cells undergoes multistage and multifactorial processes ( Figure 1) . A model proposed by Fonseca et al. 13 explains that after interaction with dendritic cells (DCs) 14 and the other supports lymphoid-resident mTfr cells. 15 cTfr cells may remigrate to follicles and GCs after reactivation. 15, 16 Signals that facilitate Tfr-cell development T-cell receptor and costimulatory signals through CD28 and ICOS are indispensable for Tfr-cell development. 5, 17, 18 Attenuated Tfr cells appear in CD28-deficient cells, 5 CD28-deficient mice 17, 18 and ICOS-deficient mice. 18 Bcl-6 is a significant TF of Tfr and Tfh cells that prompts the expression of CXCR5. Deletion of Bcl-6 in cells or in mice results in the absence of Tfr production. 5, 7 Foxp3 and chromatin-modifying enzyme Ezh2 prompt suppressive capacity and the transcriptional programme of Tfr cells. 19 Once they lose Foxp3 expression, they turn into ex-Tfr cells with an aberrant transcriptional programme and impaired suppressive capacity. Ezh2-deficient Tfr cells also exhibit reduced suppressive function by altering the Tfr-cell transcriptional programme distinct from Foxp3. 20 SOCE also regulates Tfr-and Tfh-cell differentiation via NFAT2-dependent molecules including PD-1, ICOS and CXCR5 and NFAT2-mediated TFs including IRF4, BATF and Bcl-6 expression. 21 In addition to upregulating CXCR5, Tfr cells also require NFAT2 for migration. 22 The role of mammalian target of rapamycin (mTOR) signalling in T-cell development and function is intricate. It is reported that mTORC1 is a negative regulator of conventional Treg-cell differentiation, while it also plays a critical role in Treg-cell homeostasis and suppressive capacity. 23 Nevertheless, both mTORC1 and mTORC2 are indispensable for Tfh-cell development. 24 In contrast, Roquin suppresses the PI3K-mTOR signalling, thereby inhibiting conversion of Treg to Tfr cells. 25 In particular, mTORC1 signalling prompts early differentiation and suppressive function of Tfr cells via p-STAT3-TCF-1-Bcl-6 axis. 26 It is found that TRAF3, TCF1/LEF1, Id2/Id3 and ICOS/P85a-osteopontin are essential for the development of Tfr cells. The ablation of TRAF3 reduces the generation of Tfr cells by inhibiting ICOS expression.
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In TCF1/LEF1-conditional knockout mice, Tfr-cell development is abolished with impaired Bcl-6 expression, and single knockout results in partial reduction of Tfr cells. 28 Members of the helix-loop-helix family Id2 and Id3 regulate specific transcription signatures of Tfr cells by modulating CXCR5 and Foxp3 expression. 29 The activation of ICOS promotes interaction of p85a (the regulatory subunit of PI3K) with osteopontin and thus maintains Bcl-6 expression. 30 miR-10a may potentially promote Tfr-cell differentiation by targeting Bcl-6 and corepressor Ncor2 simultaneously, thereby diminishing the conversion of Treg cells to Tfh cells. 31 
Signals that inhibit Tfr-cell development
The balance between Blimp-1 and Bcl-6 is subtle for the development of Tfr cells. Tfr cells express Blimp-1 and Bcl-6 simultaneously, whereas Tfh cells express only Bcl-6. 18 Therefore, the PD-1-PD-L1 pathway can inhibit differentiation and function of Tfr cell. However, PD-1 À/À Tfr cells are able to home to GCs.
The addition of soluble OX40L results in increased immunoglobulin generation in a 35 It is conjectured that miR-15b/16 may inhibit Tfr-cell development, as they repress the expression of Rictor and mTOR, which are essential for early differentiation and effector function of Tfr cells. 26, 36 The roles of miR-17-92, miR-155, IL-2, STAT-3 and AKT remain elusive. The miR-17-92 cluster is found to promote the differentiation of Tfr cells by targeting Pten and promoting PI3K/AKT/mTOR signalling using genetic overexpression cells. 25 In addition, miR-17-92 is validated to promote Tfhcell differentiation, and the inhibition of Pten is implicated in their early differentiation. 37 While an increased ratio of Tfr/Tfh cells is also found in chronic GVHD mice conditionally deficient for miR-17-92, whether the underlying mechanism is attributed to selective inhibition of Tfr cells or increased apoptosis in Tfh cells deserves more investigation. 38 miR-155 overexpression results in the lack of Tfr cells by inhibiting the expression of CTLA-4. 39 Conversely, it is speculated that miR-155 might promote Tfr-cell differentiation by inhibiting SOCS1. 40 High IL-2 levels preclude Tfrcell development by promoting Blimp-1, 41 while dnTGF-bRII Il2ra À/À mice have impaired Tfr-cell development, which may be mediated by regulating Bcl-6 and Nrp-1 expression. 42 The activation of p-STAT3 by IL-21 counteracts Tfr cellmediated inhibition of Tfh cells. 34 However, the deletion of STAT3 in Treg cells also results in loss of Tfr cells with enhanced generation of antigenspecific IgG. 43 Likewise, mTORC1 signalling prompts Tfr-cell development by activating STAT3. 26 AKT is required for regulating the proliferation and survival of B cells. 44 The transfer of Tfr cells into experimental autoimmune myasthenia gravis (EAMG) mice downregulates p-AKT and thus inactivates AKT in B cells. 32 Paradoxically, inhibition of p-AKT by IL-21 downregulates Foxp3 expression and therefore impairs Tfr-cell commitment. 34 
MECHANISMS OF TFR-CELL EFFECTOR FUNCTION

Bcl6
fl/fl Foxp3 cre mice (Tfr cell-specific depletion) exhibit lower levels of IgG, increased levels of IgA and decreased avidity to human immunodeficiency virus (HIV)-1 antigen. 45 In addition, higher levels of IFN-c, IL-10 and IL-21 are produced in Tfh cells from Bcl6 À/À mice. The alteration in the cytokine milieu may influence the selection of B cells, ultimately resulting in abnormal GC reactions. CTLA-4 is intended to serve as a vital mediator for Tfr cells to fully exert suppressive function. [46] [47] [48] Deletion of CTLA-4 results in compromised effector function of Tfr cell with accumulating Tfr cells. 46, 47 As a coinhibiting molecule, CTLA-4 may downregulate costimulatory ligands B7-1 and B7-2 on antigen-presenting cells 49 and directly control Tfh-cell differentiation by regulating CD28 engagement. 50 Follicular regulatory T cells inhibit the expression of specific effector genes and central metabolic (i.e. Myc and mTOR) and anabolic (i.e. serine biosynthesis and one-carbon metabolism, and purine metabolism) pathways in GC B and Tfh cells. 35 In addition, Tfr cells suppress IL-10 production by Tfh cells and in the coculture supernatants. 16 Consistent with its suppressive function, IL-10 inhibition impedes GC responses and humoral immunity. 56 Nonetheless, another study found that Tfr cell-derived IL-10 promotes B-cell differentiation and GC responses by inducing nuclear FOXO1 translocation in activated B cells, contributing to the dark zone phenotype and affinity maturation during acute viral infection. 57 
TFR CELLS IN HUMAN DISEASES AND ANIMAL MODELS
Little is known about the physiological role and mechanisms of Tfr cells because of their relatively recent studies. Nevertheless, Tfr cells have already been associated with a variety of human diseases, predominantly autoimmune diseases (AIDs; Figure 2 ). Considering the relative difficulty in obtaining samples from human lymphoid tissues, circulating Tfr (cTfr) cells and circulating Tfh (cTfh) cells have been regarded as the surrogate populations to investigate GC responses in most studies. Although these studies have suggested critical roles that Tfr cells play in various disease settings, many of them emphasise the correlation between numerical alterations of Tfr cells and disease manifestations, devoid of in-depth mechanism research.
Tfr cells in autoimmune diseases
Altered frequencies and/or the suppressive capacity of cTfr cells have been elucidated in a multitude of AIDs, including systemic AIDs and organ-specific AIDs (shown in Table 1 ). Systemic AIDs involve rheumatoid arthritis (RA), [58] [59] [60] [61] [62] systemic lupus erythematosus (SLE), 33 ,63-65 Sj€ ogren's syndrome (SS), 14, 66, 67 ankylosing spondylitis (AS), 68 IgG4-related disease (IgG4-RD) 69 and common variable immune deficiency (CVID). 70 Organ-specific AIDs involve multiple sclerosis (MS), 15 ,71,72 myasthenia gravis (MG), [73] [74] [75] Hashimoto's thyroiditis (HT), 76 primary biliary cholangitis (PBC), 77 type 1 diabetes (T1D) 78 and ulcerative colitis (UC). 79 It is also demonstrated that when the regulatory capacity of Tfr cells is impaired, the expansion of Tfr cells is accompanied by the development of autoimmunity in mice. 13, 46, 47 Increased 58,61 and decreased 59, 60 frequencies of cTfr cells are found in RA patients, while no significant difference is found in early-stage RA.
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The frequency of cTfr cells has negative 58, 60 or no correlation 59 with disease activity, and the ratio of cTfr/cTfh is correlated with disease activity. 59, 61 Moreover, increased cTfr cells with enhanced suppressive function and activated CD45RA À Foxp3 high cTfr subset have been found in patients with RA in stable remission compared with patients with active RA and healthy controls. 58 Percentages of cTfr and cTfh cells are decreased when prescribed with methotrexate. 61 Intriguingly, divergences are also observed in patients with SLE. Lower frequencies of cTfr cells were observed in two studies, 64,65 while they were higher in another study. 63 Despite the total reduction in one study, active subpopulations PD-1 high ICOS high Tfr cells and Ki-67 + Tfr cells are increased in SLE patients. 64 The frequency of cTfr cells is negatively correlated with serum antidsDNA antibody levels and with disease activity 64 and is significantly lower in seropositive antidsDNA patients than in seronegative anti-dsDNA patients. 65 In contrast, another study has found a positive correlation with clinical severity and autoantibodies IgG and IgA. 63 The suppressive function of cTfr cells is not altered in newly diagnosed SLE patients. 
CXCR5
+ Foxp3 + Tfr cells are found in spleens from BXD2 autoimmune lupus mice. 80 In the presence of NFAT2-deficient Tfr cells, the expression of CXCR5 is downregulated, and lupuslike disease is exacerbated in chromatinimmunised mice. 22 Elevated cTfr levels and cTfr/cTfh ratios in SS patients have reached a consensus, 14, 66, 67 especially in patients with high autoantibody levels. 14 The expression of PD-1 on cTfr cells is increased.
66 Activated PD-1 + ICOS + cTfh cells are closely associated with SS disease activity compared with patients with non-SS/sicca syndrome, and the increased ratio of cTfr/cTfh indicates the formation of ectopic lymphoid structures within minor salivary glands, typically in patients with focal sialadenitis. 67 Furthermore, cTfr cells do not preferentially inhibit humoral responses because of the lack of full B cellsuppressive capacity, limiting class switch recombination, and they show a na€ ıve-like phenotype. These cells are not emerged from the thymus but are produced in peripheral lymphoid organs during the GC reaction, leaving the tissue and then entering the blood. 14 Thus, the increased frequency of the cTfr cells indicates ongoing humoral activity, 14 and the cTfr/cTfh ratio is suggested to be considered as a strong predictor of SS diagnosis and focal sialadenitis in patients suffering sicca symptoms. 67 Impaired cTfr cells contribute to decreased saliva flow rates and enhanced salivary gland-specific antibodies, tissue destruction and IgG deposition in a mouse experimental SS model, indicative of the development of disease. 81 Percentages of cTfr cells and cTfh cells are significantly higher in patients with AS. 68 In addition, the frequency of cTfr cells is negatively associated with serum IgA in AS patients before treatment and is negatively associated with cTfh cells and the level of serum IL-21 after 1 month of standard treatment in drug responders. 68 
IL-10
+ -producing cTfr cells are increased in patients with IgG4-RD. 69 In addition, the frequency of cTfr cells is positively correlated with serum IgG4, ratio of IgG4/IgG, number of organs involved and soluble IL-2 receptor in IgG4-RD patients. The percentages of blood and tonsillar Tfr cells are increased with ageing, especially at the ages of IgG4-RD high prevalence.
The frequency of cTfr cells is decreased only in CVID patients with ≤2% of IgD 
CD25
high CD127 low cells. In MS patients, significantly lower frequencies of cTfr cells were found in two studies, 15, 71 as are Tfr cells in cerebrospinal fluid. 71 In addition, a lower cTfr/ cTfh ratio is related to higher IgG production and circulating B-cell percentage. 71 Notwithstanding, in patients with early clinical phase clinically isolated syndrome, a neurological disturbance often occurs before the development of MS, and the proportions of cTfr cells and cTfh cells are not significantly different from healthy controls. 72 Specifically, proportions of proinflammatory Th17-like cTfr cells 15 and cytokine-producing CD45RA
À
Foxp3
lo non-cTfr cells 72 are increased, while the proportion of suppressive fraction CD45RA
+
Foxp3
lo resting cTfr cells 72 is reduced in MS patients, which may explain the impaired suppressive function of cTfr cells. This impairment may be because of a defect in CTLA-4 signalling and that the most potent Tfr cells home to the lymph organs to inhibit the ongoing GC response. 15 Decreased cTfr cells are found in MG patients compared with healthy controls. [73] [74] [75] The ratio of cTfr/cTfh is positively correlated with the expression of the autoimmune regulator gene in peripheral blood 73 but negatively correlated with the disease severity of MG. 73, 74 In addition, a significantly decreased frequency of cTfr cells and an increased frequency of cTfh cells are observed in generalised MG (GMG) patients compared with untreated ocular MG (OMG) patients, 74 and the cTfr/cTfh ratio is the lowest in the GMG patients, as compared to the OMG patients, and higher in healthy controls. 73 After glucocorticoid treatment, cTfr cells and cTfh cells in MG patients restore immune homeostasis. Unless stated in the corresponding text, frequencies of Tfr cells and Tfh cells and the suppressive function of Tfr cells are compared between patients and healthy subjects; ↓, lower level compared with healthy subjects; ↑, higher level compared with healthy subjects; -, no statistically significant difference between patients and healthy subjects. ACPA, anticitrullinated protein antibodies; AIDs, autoimmune diseases; AS, ankylosing spondylitis; CRP, C-reactive protein; cTfh, circulating follicular helper T; cTfr, circulating follicular regulatory T; CVID, common variable immune deficiency; DAS28, disease activity score in 28 joint; dsDNA, double-stranded DNA; ESR, erythrocyte sedimentation rate; GMG, generalised myasthenia gravis; HT, Hashimoto's thyroiditis; IgG, immunoglobulin G; IgG4-RD, IgG4-related disease; MG, myasthenia gravis; MS, multiple sclerosis; NA, not available; PA-IgG, platelet antibody IgG; PBC, primary biliary cholangitis; PLT, platelet counts; RA, rheumatoid arthritis; RF, rheumatoid factor; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; smB, switched memory phenotype B cells; SS, Sj€ ogren's syndrome; T1D, type 1 diabetes; Tfr, follicular regulatory T; UC, ulcerative colitis.
Decreased cTfr cells and increased cTfh cells are found in patients with PBC. 77 94 and acute respiratory distress syndrome (ARDS) 95 have also been under investigation (shown in Table 2 ).
Tfr cells in infections
A greater proportion of Tfr cells is found in chronically HIV
+ spleens, 87 lymphoid tissues 84, 85 and tonsils. 84, 87 The expansion of Tfr cells is mediated by HIV viral replication, IDO and TGF-b signalling, enhanced proliferation and weakened apoptosis, and regulatory DC. 85 Moreover, tonsil Tfr cells exhibit increased regulatory function and dysregulated activity of Tfh cells during HIV infection. 85 Tfr cells are highly permissive to R5-tropic HIV-1, probably because of the elevated expression of CCR5 and an enhanced proliferative state, and the heightened permissivity leads to persistent HIV-1 replication in vivo. 84 
Tfr cells are reduced during acute SIV infection, and the decreased ratio of Tfr/Tfh, rather than the frequency of Tfr cells, is correlated with antidsDNA antibody and antiphospholipid antibody levels. 96 In addition, the frequency of Tfr cells is negatively correlated with the avidity of antibodies recognising SIV-gp120. 98 The percentage of Tfr cells is also increased during chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, 82, 83, 88 which is more pronounced in patients with liver cirrhosis 82 and HBeAg + chronic hepatitis B (CHB). 88 The percentage of IL-10-producing tonsillar Tfr cells is increased, and the expression of CTLA-4 on Tfr cells is upregulated. 83 In addition, the frequency of cTfr cells and the ratio of cTfr/cTfh are positively correlated with fibrosis index based on four factors and the aspartate transaminase-to-platelet ratio index. 82 Conversely, one study found that an increased number of cTfr cells are accompanied by higher levels of serum HBV DNA, HBsAg and serum alanine transaminase (ALT) in CHB patients and HCV RNA and ALT in chronic hepatitis C (CHC) patients, 88 while another study indicated no correlations between cTfr cells and HBV DNA and ALT. 82 The suppressive capacity of Tfr cells against Tfh cells is enhanced after exposure to HCV. 83 The percentage of cTfr cells is also increased in patients with schistosomiasis, and most are CD45RA À cTfr cells, reflecting memory-like properties. 86 It seems that the increase in Tfr cells in infections has gained consensus in humans. However, divergences exist in mouse models. Both cTfr cells and cTfh cells were observed to be expanded in mice infected with influenza. 16, 99 Botta et al. 41 found that Tfr cells in the lungdraining mediastinal LNs fail to accumulate at the peak of influenza infection, but after the immune response subsides, a fraction of Treg cells downregulates CD25 and then differentiates into Tfr cells. Tfr cell-deficient mice exhibit enhanced immunity to influenza viruses, indicating that Tfr cells may be targets in infectious disease. 81 Using mice infected with orthopox and influenza A viruses, it was observed that Tfh cells expand more prominently than Tfr cells and that both lymphoid and circulating Tfh/Tfr ratios can be regarded as early predictors of long-lived protective humoral immune responses. 100 
Tfr cells in cancers
Tfr cells in allergies
Frequencies of Tfr cells are found to be lower in peripheral blood from post-transplant food allergy patients 93 and in tonsils from allergic rhinitis (AR) patients.
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The phenotype and number of cTfr cells are correlated with tonsillar Tfr cells. 92 Moreover, cTfr cells in AR patients show impaired function specifically in suppressing IgE expression rather than other immunoglobulin types. The number and function of cTfr cells are negatively correlated with antigen-specific IgE production and disease activity in AR patients. Once patients get relief after allergen immunotherapy, the frequency and function of cTfr cells are recovered. 92 Tfr cells have also been investigated in a food allergy mouse model to measure peanut-specific antibody responses. 53 
Tfr cells in other disease settings
In renal transplant patients with chronic renal allograft dysfunction, frequencies of Tfr cells in peripheral blood and renal grafts from those with antibody-mediated rejection (AMR) are significantly decreased, while the frequency of IL-21-producing Tfh cells is increased, relative to those non-AMR patients. 94 However, Tfr cells exhibit equivalent suppressive function between AMR and non-AMR patients. An increase in the Tfr-cell ratio inhibits the expression of IL-21 in Tfh cells, the proliferation and differentiation of B cells, and IgG and IgA secretion of plasma cells. 94 The miR-17-92 cluster is proved to facilitate Tfhcell differentiation and impair Tfr/Tfh balance, thus accelerating the development of chronic GVHD in mice. 38 In addition, Tfr cells prompt lymphangiogenesis and Breg proliferation, exerting an atheroprotective effect in Apoe 
Tfr cells in vaccine responses
The number of cTfr cells is increased after influenza vaccination in healthy subjects 14, 15 
Tfr cells in ageing
The expansion of Tfr cells in ageing is corroborated in patients with NSCLC 90 and IgG4-RD. 69 The percentages of cTfr cells and cTfh cells are higher in patients older than 60 years, but the cTfr/cTfh ratio is decreased with age. 90 Nevertheless, the suppressive capacity of Tfr cells decreases with ageing. 69 Both Tfr cells and Tfh cells expand with age in mice, 99, 102 and Tfr cells are more pronounced. 102 However, male mice exhibit a higher percentage of Tfr cells than their female counterparts regardless of age. 99 Aged and young Tfr cells exhibit identical suppressive capacity but a distinct phenotype with enhanced PD-1 and decreased ICOS expression. 102 
CHALLENGES AND UNSOLVED QUESTIONS OF TFR CELLS
Despite the fact that great progress has been made in the physiology of Tfr cells in recent years, much is unknown, and significant phenotypic and functional heterogeneity of Tfr cells still exists among various disease settings. The uniform methodology to identify and purify Tfr cells is a technical challenge. Actually, the defining markers such as Foxp3, CD25 103 Table 3 ). However, the kinetics of LN Tfr cells are found to be similar to those of cTfr cells. 18 It is acknowledged that cTfr cells are derived from lymphoid tissues and are at least activated by DC. [14] [15] [16] Two studies conducted in patients with X-linked agammaglobulinaemia 14 and anti-CD20 antibody rituximab treatment, 107 both B cell-deficient, found that cTfr-and cTfhcell populations are not influenced. In addition, cTfr cells comprise a phenotypically distinct population compared with GC Tfr cells, displaying similar or lower levels of CXCR5 and lower or even no ICOS, PD-1 or Bcl-6.
14-16 Resembling, 15 attenuated 16 and incomplete 14 effector function of cTfr cells is described by sorting cTfr cells with distinct strategies. RNA-seq has also validated that cTfr cells separate from GC Tfr cells, and even LN Tfr cells only partially overlap with splenic Tfr cells in mice immunised with NP-OVA. 19 More specifically, LN Tfr cells exhibit higher levels of ICOS and CTLA-4, similar levels of Ki-67, but lower levels of PD-1 relative to splenic Tfr cells. When comparing their suppressive ability, LN Tfr cells are more potent for inhibiting class switching than splenic Tfr cells. 19 Thus, whether cTfr cells can be regarded as an alternative to investigate bona fide Tfr cells needs more validation. cTfr cells might have the capacity to home to secondary lymphoid organs after reactivation 15, 16 and recirculate quickly (about a few hours) through the blood, 16 whereas their putative remigration and subsequent reactions have not yet studied.
Animal models are generally used to reflect putative human physiology and pathology. Studies by two groups have revealed differences in cTfr function between humans and mice. Sage et al. 16, 18, 35, 46 showed that cTfr cells in mice can inhibit antibody generation, while Fonseca et al. 14 reported that cTfr cells in humans are not fully suppressed. Partly because of environmental exposure, murine immune system and immune responses are actually different from those of humans. 108 From this viewpoint, applications of murine knowledge directly to humans are circumscribed. Furthermore, the origin and TCR repertoire of Tfr cells have been studied only in mice.
Generally speaking, Tfr cells are deemed as repressors of GC reactions, so it is speculated that decreased Tfr/Tfh ratios are associated with enhanced autoantibody generation. Nevertheless, the alterations of Tfr cells in homogeneous diseases are inconsistent and even opposite. Study participants with different stages of the disease and therapeutic regimens may account for part of the reason because methotrexate, a first-line medication for RA, has reduced the frequencies of both Tfr and Tfh cells. 61 In addition, distinct markers to define Tfr cells in the same anatomic locations and the same markers to define Tfr cells in distinct anatomic locations have brought about great confusion. A possible interpretation for increased Tfr cells in autoantibody-mediated diseases is that it is a compensative response as a result of increased frequency of Tfh cells, attempting to restore immune homeostasis. Another is that suppressive function of Tfr cells is impaired in disease settings; thus, the overall effect of controlling GC responses is still attenuated. In addition, it has also been proposed that the microenvironment while thymic Treg cells differentiate into eTfr cells has altered so that eTfr cells have difficulty in getting access to GCs, leaving them in the peripheral blood.
Also 45 Furthermore, Tfr cells help maintain high levels of high-affinity antigen-specific antibodies 5, 45 and regulate the isotype switch of antibodies. 45 They also promote the GC response through the secretion of IL-10 and the suppression of cytotoxic Tfh cells. 53, 57 Thus, Tfr cells might play a complicated role in the fine-tuning of GC response and act as 'helper cells' in certain scenarios.
Recently 
PERSPECTIVES
The discovery of Tfr cells has provided novel insights into the regulation of humoral immunology, although it is still in the nascent stage. Future emphasis should be put on intricate factors that influence the differentiation and 113 LN FNAs have already been applied in a pioneering longitudinal study for human GC investigation. 114 Undoubtedly, the establishment of a precise definition of Tfr cells in different anatomic locations and relevant animal models is of equal importance. Substantial discrepancies and problems remain to be solved, and these answers will undoubtedly improve immunotherapy. 
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